Many breast cancer patients can skip chemo, landmark study finds
The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the U.S. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 3, 2018 Category: Consumer Health News Source Type: news

Many breast cancer patients can skip chemo, big study finds
The largest study ever done of breast cancer treatment finds that most women with the most common form of the disease can skip chemotherapy without hurting their chances of beating the cancer (Source: ABC News: Health)
Source: ABC News: Health - June 3, 2018 Category: Consumer Health News Tags: Health Source Type: news

Breast cancer study set to free women from chemotherapy
Trials find no benefit from gruelling treatment for most patients diagnosed in early stages of disease (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - June 3, 2018 Category: Pharmaceuticals Source Type: news

Many women with early-stage breast cancer can skip chemotherapy: study
CHICAGO (Reuters) - Some 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely skip chemotherapy after their tumors have been removed, U.S. researchers said on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

For Some Breast Cancer Patients, The Chemo Decision Just Got Easier
Thousands of breast cancer patients could now safely avoid chemotherapy thanks to a major study of women with moderate risk of recurrence.(Image credit: Lester Lefkowitz/Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - June 3, 2018 Category: Consumer Health News Authors: Sara Kiley Watson Source Type: news

Breast cancer: Test means fewer women will need chemotherapy
From Monday, about 70% of women with early stage cancer may be able to avoid the gruelling treatment. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - June 3, 2018 Category: Consumer Health News Source Type: news

Good News for Women With Breast Cancer: Many Don ’ t Need Chemo
Many women with early-stage forms of the disease can forego chemo, based on a test that measures the activity of genes involved in breast cancer recurrence. (Source: NYT Health)
Source: NYT Health - June 3, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Chemotherapy Tumors Hormones Tamoxifen (Drug) American Society of Clinical Oncology Genomic Health Inc Tests (Medical) Source Type: news

TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy
The new data will help inform treatment decisions for many women with early-stage breast cancer. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - June 3, 2018 Category: American Health Source Type: news

Many Breast Cancer Patients Can Safely Skip Chemo, Large Trial Confirms
The public health implications are huge. If we give chemotherapy only to breast cancer patients at high risk for recurrence, we can avoid overtreating. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 3, 2018 Category: Pharmaceuticals Authors: Elaine Schattner, Contributor Tags: NASDAQ:GHDX Source Type: news

Gene Test May Allow Many With Early Breast Cancer to Avoid Chemo
SUNDAY, June 3, 2018 -- A majority of women with an early form of a common breast cancer may be able to skip chemotherapy, depending on the results of a comprehensive gene test. The new study of nearly 7,000 women found that use of the already... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 3, 2018 Category: General Medicine Source Type: news

TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy
(ECOG-ACRIN Cancer Research Group) " Before TAILORx, there was uncertainty about the best treatment for women with a mid-range score of 11-25 on the Oncotype DX Breast Recurrence Score test. The trial was designed to address this question, and provides a very definitive answer, " said lead investigator Joseph A. Sparano, MD. " Any woman with early-stage breast cancer 75 years or younger should have the 21-gene expression test and discuss the results with her doctor to guide her decision to the right therapy. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2018 Category: International Medicine & Public Health Source Type: news

Landmark study finds more breast cancer patients can safely forgo chemotherapy
(Loyola University Health System) A 21-gene test performed on tumors could enable most patients with the most common type of early breast cancer to safely forgo chemotherapy, according to a landmark study published in the New England Journal of Medicine.Loyola Medicine oncologist Kathy Albain, M.D., is among the main co-authors of the study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2018 Category: International Medicine & Public Health Source Type: news

Gene Test May Allow Many With Early Breast Cancer to Avoid Chemo
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 3, 2018 Category: Cancer & Oncology Source Type: news

Ambry Genetics in Collaboration with Mayo Clinic and NorthShore...
Ambry’s polygenic risk score (PRS) can provide clinicians with individualized breast cancer risk estimates(PRWeb June 03, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15531043.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 3, 2018 Category: Pharmaceuticals Source Type: news

Gene Test May Allow Many With Early Breast Cancer to Avoid Chemo
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 3, 2018 Category: Cancer & Oncology Source Type: news

Taselisib Hits, but Barely Slows, PI3KCA-Mutated Breast Cancer Taselisib Hits, but Barely Slows, PI3KCA-Mutated Breast Cancer
The investigational targeted therapy is somewhat effective, but has the downside of significant additional toxicity.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Taselisib Modestly Delays Progression in ER+ Breast Cancer
Bryant FurlowJun 2, 2018The PI3K inhibitor taselisib offered less dramatic clinical benefits than anticipated, and with significant toxicities. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Trial Breast Cancer Drug Shows 'Modest' Benefit
As the researchers explained, taselisib has already proven beneficial for people fighting head-and-neck cancers or certain gynecological tumors. Would it do the same for hormone-sensitive breast cancers? (Source: WebMD Health)
Source: WebMD Health - June 2, 2018 Category: Consumer Health News Source Type: news

Roche drugs show limited benefit in lung, breast cancer trials
CHICAGO (Reuters) - In a disappointment for Roche Holding AG, two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials presented on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - June 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Experimental Drug, Taselisib, Shows'Modest' Benefit in Slowing Advanced Breast Cancer
SATURDAY, June 2, 2018 -- A new and highly targeted drug slowed the growth of advanced breast cancers by about an average of two months, researchers report. " The findings in this study show a modest benefit to a subgroup of women with estrogen... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 2, 2018 Category: General Medicine Source Type: news

Experimental Drug Shows'Modest' Benefit in Slowing Advanced Breast Cancer
SATURDAY, June 2, 2018 -- A new and highly targeted drug slowed the growth of advanced breast cancers by about an average of two months, researchers report. " The findings in this study show a modest benefit to a subgroup of women with estrogen... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 2, 2018 Category: General Medicine Source Type: news

Experimental Drug Shows 'Modest' Benefit in Slowing Advanced Breast Cancer
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 2, 2018 Category: Cancer & Oncology Source Type: news

NHS cancer patients 'failing to be correctly monitored'
Concerns expressed that opportunities to save lives may be missedCancer patients in the UK may not receive enough follow-up after a diagnosis, a new study by researchers in Chicago suggests.The study, presented at the annual American Society of Clinical Oncology in Chicago, suggests five years of monitoring is insufficient for some cancers and too long for others. The research suggests some NHS patients may receive too few years of follow-up care.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 1, 2018 Category: Science Authors: Jessica Glenza in Chicago Tags: Cancer Cancer research Breast cancer Bowel cancer Cervical cancer Lung cancer Ovarian cancer Pancreas cancer Prostate cancer Health Medical research Science Society UK news Source Type: news

40 Under 40 honoree wants to ensure no woman has to go through breast cancer alone
Maliha Mian's breast cancer journey was lonely. So she created a platform for education, help and solidarity. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 1, 2018 Category: American Health Authors: Natalie Harms Source Type: news

40 Under 40 honoree wants to ensure no woman has to go through breast cancer alone
Maliha Mian's breast cancer journey was lonely. So she created a platform for education, help and solidarity. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 1, 2018 Category: Biotechnology Authors: Natalie Harms Source Type: news

Adding Ribociclib Improves PFS in Premenopausal Breast Cancer
Dave LevitanJun 1, 2018Ribociclib plus endocrine therapy resulted in improved progression-free survival in premenopausal women with HR-positive, HER2-negative advanced breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Roche's Perjeta wins approval in Europe for expanded use
ZURICH (Reuters) - Roche's on Friday won European Union approval for its Perjeta medicine to treat a type of breast cancer whose sufferers are at a high risk of re-occurrence, the Swiss drugmaker said in a statement. (Source: Reuters: Health)
Source: Reuters: Health - June 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - June 1, 2018 Category: Pharmaceuticals Source Type: news

Siemens Healthineers gets in on $5m round for ScreenPoint Medical
ScreenPoint Medical drummed up $5.0 million in a funding round led by the healthcare business at Siemens (NYSE:SI), saying it’s earmarked the proceeds for its Transpara mammography evaluation software. Siemens Healthineers was joined by private investors in the €4.3 million round, Nijmegen, Holland-based ScreenPoint said. The Transpara software uses deep learning and image databases to aid in evaluating mammograms. The collaboration doesn’t stop at cash, as ScreenPoint said a strategic collaboration in precision medicine for breast imaging is in the works with the German conglomerate. T...
Source: Mass Device - June 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Imaging Software / IT Wall Street Beat Women's Health ScreenPoint Medical Siemens Healthineers Source Type: news

PHOTOS: Mercy opens new Women ’s Imaging Center in Roseville
It ’s a project that’s been over two years in the making, but Mercy Imaging Centers, a division of Dignity Health, has started scheduling appointments for its new Roseville Women’s Imaging Center. Mercy’s new center will chiefly provide breast cancer screening services. It’s located at 1380 Lead Hill Blvd. in Roseville and is one of the newest additions to the South Placer Business Park. Mercy spent $3.6 million renovating the 8,000-square-foot building. “It was an empty shell; nothing… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 1, 2018 Category: Pharmaceuticals Authors: Kayla Webster Source Type: news

Medical News Today: Is there a link between breast-feeding and breast cancer?
It is possible, though rare, to develop breast cancer while breast-feeding. However, there are many other possible causes of breast lumps in lactating women. In this article, we look at the link between breast cancer and lactation. We also explain what to do if you find a breast lump while breast-feeding. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 1, 2018 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Many Breast Cancer Survivors Not Getting Needed Mammograms
Title: Many Breast Cancer Survivors Not Getting Needed MammogramsCategory: Health NewsCreated: 5/31/2018 12:00:00 AMLast Editorial Review: 6/1/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 1, 2018 Category: Cancer & Oncology Source Type: news

Irradiating chest lymph nodes in patients with early stage breast cancer improves survival without increasing side effects
(European Organisation for Research and Treatment of Cancer) Giving radiation therapy to the lymph nodes located behind the breast bone and above the collar bone to patients with early stage breast cancer improves overall survival without increasing side effects, and this effect continues for 15 years, researchers have found. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news

Many Breast Cancer Survivors Not Getting Needed Mammograms
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 1, 2018 Category: Cancer & Oncology Source Type: news

Complaint asks state accounting board to revoke Clark Nuber's license, alleges deceptive practices
The Bellevue firm did the accounting for the Breast Cancer Prevention Fund, which the IRS found had been funneling millions of dollars to a for-profit company with the same owner. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 31, 2018 Category: Biotechnology Authors: Coral Garnick Source Type: news

Despite risk of breast cancer, few men undergo genetic tests, study finds
Cancer is one of the leading causes of death among Americans. At least 10 percent of cancers are caused by inherited mutations in genes such as BRCA1 and BRCA2. Parents with the cancer gene mutation have a 50 percent chance of passing it on to a son or daughter. It ’s well-known that women with BRCA are at a very high risk for breast and ovarian cancer. Less known is the fact that men with these mutations also are at risk of breast cancer and other cancers.Astudy published in April in JAMA Oncology finds that few men are screened for these genetic mutations — and the researchers strongly suggest that they be sc...
Source: UCLA Newsroom: Health Sciences - May 31, 2018 Category: Universities & Medical Training Source Type: news

QuickStats: Breast Cancer Death Rates Among Women Aged 50 –74 Years, by Race/Ethnicity — National Vital Statistics System, United States, 2006 and 2016
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - May 31, 2018 Category: American Health Source Type: news

Many Breast Cancer Survivors Not Getting Needed Mammograms
THURSDAY, May 31, 2018 -- After surviving a diagnosis of breast cancer, women still need regular screening. But many of them, especially black women, aren't getting the mammograms they need, a new study finds. It's essential to screen for a return... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 31, 2018 Category: General Medicine Source Type: news

Mother with incurable breast cancer has to raise £1,000 a month
Lesley Kennedy, from Belfast, has chosen to try palbociclib, a drug hailed as the ‘closest thing to a cure’ for women with incurable breast cancer. But she isn't eligible for NHS funding. (Source: the Mail online | Health)
Source: the Mail online | Health - May 31, 2018 Category: Consumer Health News Source Type: news

Mother-of-three with incurable breast cancer has to raise £1,000 a month for drug
Lesley Kennedy, from Belfast, has chosen to try palbociclib, a drug hailed as the ‘closest thing to a cure’ for women with incurable breast cancer. But she isn't eligible for NHS funding. (Source: the Mail online | Health)
Source: the Mail online | Health - May 31, 2018 Category: Consumer Health News Source Type: news

Yoga found to be effective at reducing fatigue and sleep disturbances in women diagnosed with breast cancer
(Natural News) Getting cancer can be one of the most challenging times in a person’s life. However, it’s a reality that some people face – such as when women face breast cancer. In the U.S., at least one in eight women will develop invasive breast cancer in their lifetime, making it one of the most... (Source: NaturalNews.com)
Source: NaturalNews.com - May 31, 2018 Category: Consumer Health News Source Type: news

Researchers uncover cell types of the human breast epithelium
(University of California - Irvine) Researchers from the University of California, Irvine School of Medicine, in collaboration with scientists at UCSF and Northwestern University, have profiled human breast epithelial cells, identifying three new distinct epithelial cell populations. The discovery of these cell populations could aid in understanding the origins of breast cancer and lead to improved early cancer detection, a slowing of cancer progression and possibly even cancer prevention. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 31, 2018 Category: Biology Source Type: news

Beyond BRCA: Links between breast, second primary cancer and inherited mutations
(University of Pennsylvania School of Medicine) Rates of inherited mutations in genes other than BRCA1/2 are twice as high in breast cancer patients who have had a second primary cancer -- including, in some cases, different types of breast cancer -- compared to patients who have only had a single breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 31, 2018 Category: International Medicine & Public Health Source Type: news

Many Breast Cancer Survivors Not Getting Needed Mammograms
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

Long-Awaited TAILORx Results'Will Impact Your Practice'Long-Awaited TAILORx Results'Will Impact Your Practice '
' Do not miss'the results of TAILORx this year at ASCO 2018, says Dr Kathy Miller, because they will likely affect management of ER-positive breast cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Circulating Tumor Cells To Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting
Study adds to significant body of evidence supporting clinical utility of CELLSEARCH BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., May 30, 2018 -- (Healthcare Sales & Marketing Network) -- Menarini Silicon Biosystems announced today that a new study has f... Diagnostics, Oncology Menarini Silicon Biosystems, circulating tumor cells, liquid biopsy, CELLSEARCH (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 30, 2018 Category: Pharmaceuticals Source Type: news

Coverage of Breast Cancer Screening and Prevention Services
This factsheet discusses breast cancer screening and prevention services, and reviews the scope of private and public insurance coverage, as well as access to those services for women in the US. (Source: HSR Information Central)
Source: HSR Information Central - May 30, 2018 Category: International Medicine & Public Health Source Type: news

TGen and Huntsman Cancer Institute receive $6.7 million grant to battle a hidden enemy
(The Translational Genomics Research Institute) In an effort to combat metastatic breast cancer, the US Department of Defense has jointly awarded a $6.7 million grant to Huntsman Cancer Institute (HCI) at the University of Utah, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. HCI will focus on the biology of an important cellular pathway in metastatic breast cancer, while TGen will focus on drug development and supervise clinical trials to test those drugs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 30, 2018 Category: International Medicine & Public Health Source Type: news